vaccin
singl
signific
advanc
public
health
prevent
morbid
mortal
million
peopl
annual
vaccin
develop
tradit
focus
whole
organ
vaccin
either
live
attenu
inactiv
vaccin
success
mani
differ
infecti
diseas
whole
organ
expens
produc
requir
cultur
infecti
agent
potenti
caus
vaccin
associ
diseas
host
advanc
technolog
desir
develop
safe
cost
effect
vaccin
candid
field
began
focu
develop
recombinantli
express
antigen
known
subunit
vaccin
toler
subunit
vaccin
tend
less
immunogen
attempt
made
increas
immunogen
addit
adjuv
either
immunostimulatori
molecul
antigen
deliveri
system
increas
immun
respons
vaccin
area
extrem
interest
applic
nanotechnolog
vaccin
develop
allow
antigen
express
particul
deliveri
system
one
excit
exampl
nanovaccin
ration
design
protein
nanoparticl
nanoparticl
use
basic
tenant
structur
biolog
biophys
chemistri
vaccinolog
develop
protect
safe
easili
manufactur
vaccin
ration
develop
nanoparticl
vaccin
one
promis
candid
futur
vaccin
develop
vaccin
one
greatest
public
health
innov
human
histori
vaccin
provid
extrem
effect
mechan
deal
infecti
diseas
prevent
develop
morbid
mortal
world
health
organ
estim
vaccin
prevent
million
human
death
annual
number
would
rise
least
million
children
receiv
recommend
vaccin
schedul
two
infecti
diseas
elimin
human
histori
result
success
vaccin
campaign
first
human
diseas
smallpox
offici
declar
elimin
human
popul
second
livestock
diseas
rinderpest
declar
elimin
diseas
measl
polio
also
close
elimin
still
much
done
infecti
diseas
vaccin
work
serv
prophylact
control
exposur
infecti
agent
initi
exposur
ideal
induc
strong
immun
respons
vaccin
individu
vertebr
immun
system
compos
two
differ
branch
innat
adapt
immun
system
follow
exposur
infecti
agent
administr
vaccin
activ
innat
immun
system
preced
gener
adapt
immun
innat
immun
system
compos
divers
array
cell
type
neutrophil
dendrit
cell
monocyt
macrophag
eosinophil
function
interact
foreign
molecul
nonspecif
manner
innat
immun
cell
phagocytos
infecti
agent
secret
inflammatori
cytokin
andor
attract
activ
immun
cell
secret
chemic
messeng
chemokin
process
lead
initi
effect
immun
respons
vaccin
ultim
depend
develop
effect
adapt
immun
respons
broadli
adapt
immun
respons
divid
two
differ
categori
humor
cellular
cell
adapt
immun
system
respond
specif
region
infecti
agent
known
epitop
one
epitop
contain
larger
molecul
known
antigen
humor
immun
respons
depend
activ
antibodi
secret
glycoprotein
b
cell
bind
specif
epitop
b
cell
contain
b
cell
receptor
surfac
vari
specif
upon
bind
b
cell
receptor
match
epitop
b
cell
matur
plasma
cell
begin
secret
epitop
specif
antibodi
ideal
lead
protect
infect
cellular
immun
respons
base
action
cell
nucleat
cell
surfac
major
histocompat
complex
class
mhci
molecul
infect
intracellular
infecti
agent
cell
abl
present
surfac
linear
epitop
infecti
agent
complex
mhci
alert
immun
system
infect
cytotox
cell
c
contain
match
cell
receptor
abl
bind
mhci
present
specif
epitop
lead
death
infect
cell
complex
class
ii
mhcii
surfac
epitop
stimul
cell
lead
matur
h
cell
activ
h
cell
abl
stimul
cell
innat
adapt
immun
system
secret
cytokin
cytokin
abl
modul
immun
respons
lead
stronger
effect
immun
respons
base
profil
secret
cytokin
respons
either
class
helper
respons
h
helper
respons
h
h
respons
favor
develop
cellular
base
immun
respons
h
respons
favor
develop
humor
immun
respons
tradit
vaccin
develop
focus
develop
strong
h
respons
current
vaccin
candid
balanc
h
h
respons
consid
optim
activ
b
cell
h
c
undergo
prolifer
effect
deal
infect
ideal
situat
cell
persist
clearanc
result
develop
immunolog
memori
previous
expos
host
expos
infecti
agent
antigenspecif
immun
memori
cell
activ
prolifer
faster
greater
magnitud
lead
rapid
clearanc
infecti
agent
mitig
diseas
strong
effect
memori
respons
protect
host
subsequ
infect
lead
lifelong
immun
hallmark
effect
vaccin
vaccin
work
organism
level
also
popul
level
concept
known
herd
immun
certain
fraction
popul
immun
infecti
agent
diseas
low
likelihood
find
anoth
host
spread
number
peopl
need
vaccin
herd
immun
vari
diseas
diseas
normal
extrem
import
given
popul
vaccin
individu
develop
protect
base
upon
genet
individu
vaccin
age
diseas
state
unvaccin
individu
herd
immun
altruist
side
vaccin
ultim
lead
elimin
pathogen
either
human
anim
popul
typic
smallpox
lesion
reason
inocul
peopl
materi
contain
cowpox
pustul
would
protect
subsequ
infect
smallpox
perform
first
known
vaccin
trial
take
cowpox
pustul
milkmaid
inocul
boy
note
boy
felt
gener
malais
day
recov
quickli
later
variol
child
smallpox
howev
child
show
sign
becom
infect
diseas
somewhat
controversi
time
jenner
spent
rest
life
public
techniqu
point
germ
theori
diseas
establish
peopl
understand
smallpox
cowpox
caus
close
relat
virus
mani
peopl
concern
vaccin
differ
diseas
would
actual
lead
protect
england
began
keep
caus
death
record
william
farr
abl
determin
commun
high
vaccin
rate
low
rate
death
smallpox
ultim
variol
ban
england
vaccin
becam
standard
prophylact
treatment
smallpox
jenner
succeed
develop
implement
world
first
vaccin
figur
tabl
french
microbiologist
chemist
loui
pasteur
made
next
major
advanc
develop
vaccin
studi
chicken
cholera
pasteurella
multocida
chicken
inocul
month
old
cultur
vacat
inocul
chicken
develop
minor
symptom
diseas
recov
later
inocul
chicken
fresh
cultur
bacteria
saw
chicken
previous
inocul
old
cultur
protect
infect
bird
still
develop
symptom
pasteur
stumbl
onto
concept
attenu
microorgan
grown
suboptim
condit
treat
certain
chemic
virul
microorgan
grown
ideal
condit
expos
chicken
attenu
bacteria
pasteur
abl
induc
protect
subsequ
lethal
challeng
virul
p
multocida
pasteur
abl
repeat
similar
find
attenu
bacillu
anthraci
vaccin
farm
anim
attenu
b
anthraci
pierr
galtier
discov
someth
saliva
rabid
dog
caus
rabi
mammal
pasteur
develop
way
propag
infecti
agent
decreas
incub
time
day
instead
month
demonstr
inocul
dog
mammal
attenu
strain
rabi
viru
anim
protect
challeng
normal
rabi
viru
year
old
joseph
meister
bitten
rabid
dog
pasteur
abl
vaccin
attenu
viru
prevent
boy
develop
rabi
tabl
pasteur
abl
demonstr
attenu
infecti
agent
could
still
result
protect
vaccin
human
subsequ
exposur
virul
infecti
agent
work
lead
develop
attenu
vaccin
typhoid
fever
cholera
plagu
late
th
earli
th
centuri
figur
also
note
anim
given
subleth
dose
purifi
toxin
develop
antidot
serum
antidot
quickli
becam
understood
antibodi
bind
toxin
antigen
specif
conform
lead
neutral
use
similar
concept
pasteur
scientist
develop
vaccin
candid
known
toxoid
vaccin
consist
diphtheria
toxin
treat
formalin
longer
toxic
anim
still
immunogen
lead
develop
antibodi
ultim
protect
diphtheria
figur
tabl
vaccin
develop
initi
slow
partial
lack
techniqu
cultur
infecti
agent
virus
intracellular
parasit
need
host
tissu
reproduc
grow
viral
cultur
depend
develop
effect
tissu
cultur
system
first
attempt
grow
anim
tissu
vitro
occur
wilhelm
roux
abl
sustain
part
chicken
embryo
salin
solut
day
next
year
techniqu
abil
scientist
maintain
anim
cultur
began
improv
midtwentieth
centuri
tissu
cultur
techniqu
matur
level
scientist
abl
propag
virus
cultur
includ
human
tissu
one
first
diseas
target
vaccin
develop
poliomyel
polio
polio
caus
one
three
strain
enteroviru
polioviru
polio
present
human
popul
sinc
record
histori
epidem
began
occur
late
nineteenthearli
twentieth
centuri
worst
record
epidem
occur
unit
state
result
case
death
case
paralysi
point
viru
alreadi
cultur
john
ender
vaccin
develop
underway
two
major
approach
develop
would
ultim
give
clue
vaccinolog
would
progress
next
year
first
approach
pioneer
jona
salk
salk
previous
work
inactiv
influenza
vaccin
believ
effect
candid
would
inactiv
polioviru
point
scientist
knew
protect
polio
mediat
immunoglobulin
g
igg
viremia
proceed
paralyt
effect
patient
salk
hypothes
inject
patient
inactiv
polioviru
would
develop
igg
respons
necessari
prevent
clinic
symptom
diseas
develop
salk
inactiv
trival
polio
vaccin
ipv
consist
one
three
differ
strain
polioviru
formalin
inactiv
develop
vaccin
perform
initi
anim
human
studi
next
two
year
clinic
studi
increas
size
ipv
determin
safe
effect
depend
strain
polioviru
contract
vaccin
approv
unit
state
incid
paralyt
polio
us
decreas
due
salk
vaccin
second
approach
use
attenu
oral
polio
vaccin
opv
scientist
believ
ipv
would
induc
long
term
protect
famou
group
albert
sabin
propos
use
attenu
viru
deliv
oral
rout
natur
infect
rout
viru
sabin
gener
four
differ
opv
candid
determin
three
attenu
viral
strain
would
ultim
wind
final
vaccin
candid
opv
candid
underw
clinic
studi
unit
state
ussr
around
world
opv
approv
unit
state
becom
wide
accept
polio
vaccin
one
major
advantag
opv
vaccin
patient
actual
becom
infect
vaccin
abl
spread
opv
virus
surround
commun
would
infect
virul
strain
viru
major
disadvantag
small
number
patient
spontan
revers
occur
attenu
vaccin
strain
lead
virul
viru
lead
vaccin
deriv
paralyt
poliomyel
vdpp
patient
surround
commun
work
salk
sabin
move
field
vaccinolog
demonstr
two
differ
approach
possibl
develop
vaccin
candid
abl
prevent
polio
epidem
method
strength
weak
world
move
use
opv
place
ipv
risk
develop
vdpp
opv
countri
elimin
diseas
tend
move
away
trival
opv
ipv
current
unit
state
use
ipv
vaccin
histori
also
highlight
frequent
chang
need
vaccin
develop
light
biolog
epidemiolog
infecti
agent
golden
age
vaccinolog
also
saw
gener
three
extrem
import
attenuatedviru
vaccin
candid
childhood
diseas
first
measl
highli
contagi
diseas
greater
peopl
eventu
develop
second
diseas
mump
final
vaccin
candid
rubella
three
vaccin
would
combin
singl
multival
attenuatedviru
vaccin
candid
measl
mump
rubella
vaccin
mmr
differ
corpor
produc
differ
formul
product
mmr
vaccin
determin
safe
effect
reduc
global
morbid
mortal
measl
mump
rubella
scientist
understand
molecular
microbi
genet
increas
new
knowledg
role
dna
cell
natur
gene
function
phage
discoveri
restrict
enzym
lead
propos
dna
molecul
could
modifi
includ
foreign
dna
earli
within
fifteen
year
techniqu
develop
gener
recombin
dna
transform
transduc
host
cell
escherichia
coli
saccharomyc
cerevisia
baculovirusinsect
cell
express
system
produc
recombin
protein
subsequ
year
express
system
develop
increas
abil
produc
recombin
protein
revolut
biolog
allow
vaccinologist
approach
concept
vaccin
new
light
work
hypothesi
use
specif
antigen
variou
infecti
agent
safe
cheap
effect
vaccin
candid
could
produc
previou
inactiv
vaccin
attenu
vaccin
toxoid
vaccin
requir
cultur
given
infecti
agent
vaccin
candid
could
develop
use
recombin
dna
technolog
protein
antigen
organ
either
uncultur
highli
pathogen
extrem
expens
cultur
could
gener
subunit
vaccin
reduc
risk
side
effect
spontan
revers
attenu
vaccin
denatur
antigen
peptid
inactiv
vaccin
subunit
vaccin
candid
almost
everi
known
human
anim
vaccin
exist
howev
major
problem
subunit
vaccin
exposur
whole
organ
vaccin
whether
inactiv
attenu
close
relat
speci
expos
subject
one
copi
antigen
vacuum
whole
organ
vaccin
contain
multipl
copi
antigen
well
immunostimulatori
molecul
result
problem
subunit
vaccin
gener
immunostimulatori
effect
like
caus
reduc
abil
cross
link
b
cell
receptor
well
reduc
abil
stimul
apc
mani
approach
taken
develop
subunit
vaccin
safe
easi
produc
also
effect
whole
organ
vaccin
one
way
vaccin
modifi
increas
efficaci
addit
adjuv
word
adjuv
come
latin
word
adiuvar
mean
help
simplest
term
adjuv
someth
help
vaccin
function
could
mean
adjuv
allow
vaccin
immunogen
induc
stronger
humor
cellular
immun
respons
increas
antigen
process
apc
decreas
total
amount
vaccin
need
inject
process
known
dose
spare
aid
develop
long
term
memori
respons
broadli
two
main
class
adjuv
immunopotenti
deliveri
system
immunopotenti
stimul
immun
system
deliveri
system
function
carri
present
vaccin
host
immun
system
adjuv
use
vaccin
formul
almost
sinc
dawn
vaccin
age
essenti
use
subunit
vaccin
despit
use
almost
centuri
adjuv
well
understood
new
vaccineimmunopotentiatordeliveri
system
formul
need
test
efficaci
toxic
first
known
wide
use
adjuv
aluminum
salt
also
known
alum
aluminum
contain
salt
current
univers
approv
adjuv
human
use
unit
state
aluminum
potassium
sulfat
first
identifi
induc
higher
titer
antibodi
guinea
pig
inject
formul
diphtheria
toxoid
comparison
toxoid
vaccin
inject
alon
subsequ
demonstr
aluminumcontain
salt
result
stronger
humor
respons
vaccin
affect
cellular
respons
exact
mechan
action
complet
understood
still
wide
debat
like
depend
vaccin
rout
inject
organ
vaccin
inject
gener
known
alum
attract
innat
immun
cell
particularli
immatur
dendrit
cell
site
vaccin
cell
abl
matur
present
vaccin
h
cell
lymph
node
subsequ
abl
stimul
b
cell
encount
vaccin
gener
high
titer
antibodi
alum
also
bind
protein
potenti
depend
vaccin
rout
function
immunopotenti
deliveri
system
anoth
major
class
adjuv
emuls
first
emuls
adjuv
gener
jule
freund
contain
miner
oil
emulsifi
agent
dri
ground
mycobacterium
tuberculosi
creat
waterinoil
emuls
formul
known
freund
complet
adjuv
fca
shown
stimul
humor
cellular
immun
pathway
ultim
presenc
tuberculosi
determin
danger
use
human
result
gener
freund
incomplet
adjuv
ifa
contain
everyth
fca
except
tuberculosi
ifa
lead
primarili
humor
respons
vaccin
eventu
ifa
use
formul
ipv
howev
use
discontinu
human
due
reactiv
initi
success
immunogen
emuls
lead
desir
creat
safer
altern
fca
ifa
would
immunogen
without
side
effect
focu
move
oilinwat
emuls
novarti
first
oilinwat
emuls
approv
europ
mixtur
squalen
span
surfact
tween
citrat
buffer
combin
antigen
believ
function
recruit
innat
adapt
immun
cell
site
inject
like
alum
mechan
complet
understood
known
induc
higher
titer
antibodi
well
c
respons
compani
laboratori
develop
oilinwat
emuls
vari
degre
success
one
slightli
differ
approv
inactiv
influenza
vaccin
europ
one
excit
area
adjuv
develop
use
pathogen
associ
molecular
pattern
pamp
adjuv
either
combin
anoth
type
adjuv
tabl
pamp
repetit
molecul
present
invad
microorgan
multicellular
organ
evolv
pattern
recognit
receptor
prr
germlin
encod
receptor
recogn
pamp
prr
present
cell
membran
tolllik
receptor
tlr
ctype
lectin
receptor
clr
other
intern
receptor
nodlik
receptor
nlr
rigilik
receptor
rlr
class
prr
subdivid
differ
receptor
specif
target
specif
signal
pathway
mani
well
understood
major
advantag
adjuv
develop
use
pamp
well
understood
vaccin
formul
develop
lead
safer
effect
immun
stimul
reduc
side
effect
adjuv
chain
middl
domain
known
core
domain
final
domain
known
lipid
lipid
respons
signal
upon
initi
stimul
signal
adapt
protein
lead
transcript
via
transcript
factor
proinflammatori
cytokin
signal
continu
endocytos
lead
signal
tramtrif
transcript
interleukini
gene
lead
antimicrobi
activ
two
respons
activ
independ
wildtyp
lp
good
adjuv
even
though
highli
immunogen
much
lp
lead
septic
shock
littl
lead
endotoxin
toler
chemic
modifi
lipid
salmonella
minnesota
remov
phosphat
group
gener
slight
alter
fatti
acid
chain
potenti
new
adjuv
gener
known
monophosporyl
lipid
mpla
mpla
signal
tramtrif
signal
pathway
prevent
gener
proinflamatori
cytokin
adjuv
shown
abl
increas
serum
antibodi
titer
well
induc
strong
cellular
immun
respons
human
time
dose
mpla
better
toler
wildtyp
lipid
adjuv
approv
combin
alum
use
cervarix
human
papilloma
viru
hpv
vaccin
unit
state
anoth
pamp
potenti
adjuv
candid
flagellin
compon
bacteri
flagellum
tabl
flagellin
monom
subdivid
four
differ
domain
highli
conserv
region
consid
variabl
region
flagellin
stimul
cell
via
conserv
domain
upon
stimul
signal
pathway
lead
activ
transcript
factor
transcript
proinflammatori
cytokin
studi
indic
flagellin
function
increas
antibodi
titer
increas
attribut
flagellin
activ
dc
well
apc
recruit
b
cell
lymph
node
lead
interact
b
cell
h
cell
lead
increas
antibodi
product
initi
studi
seem
indic
flagellin
strong
adjuv
c
respons
howev
repeatedli
demonstr
function
regard
well
flagellin
also
abl
activ
inflammasom
via
amino
acid
present
c
terminu
domain
amino
acid
abl
interact
prr
role
inflamosom
regard
adjuv
function
complet
clear
unmethyl
cpg
motif
also
current
investig
potenti
adjuv
tabl
bacteria
frequent
methyl
cpg
motif
howev
vertebr
allow
differenti
foreign
dna
natur
infect
process
cpg
motif
recogn
present
endoplasm
reticulum
er
late
endosom
compart
lysosom
compart
differ
organ
local
differ
cell
type
frequent
local
plasmacytoid
dc
b
cell
human
upon
stimul
exit
er
interact
lead
activ
signal
pathway
lead
activ
product
h
proinflamatori
cytokin
increas
innat
adapt
immun
respons
adjuv
use
synthet
cpg
oligodeoxynucelotid
cpg
odn
gener
contain
unmethyl
cpg
gener
cpg
odn
contain
karch
clinic
trial
use
cpg
adjuv
perform
wide
rang
infecti
diseas
result
increas
immunogen
vaccin
test
effect
rang
increas
antibodi
product
faster
memori
respons
chang
cytokin
profil
vaccin
lead
stronger
immun
respons
rna
bind
tlr
also
examin
potenti
target
adjuv
develop
tabl
local
endosom
primarili
present
plasmacytoid
dc
b
cell
primarili
present
monocytesmacrophag
myeloid
dc
receptor
bind
singl
strand
rna
sequenc
infect
microorgan
synthet
agonist
imiquimod
bind
synthet
agonist
resiquimond
stimul
lead
signal
activ
ultim
proinflammatori
cytokin
short
halflif
rna
necessit
develop
success
long
last
vaccin
formul
one
synthet
agonist
use
initi
studi
indic
agonist
immunostimulatori
given
topic
ointment
howev
given
admix
inject
extrem
high
dose
necessari
subsequ
studi
determin
fusion
agonist
given
antigen
admixtur
pamp
newer
agonist
design
show
promis
success
adjuv
candid
addit
chemic
biolog
adjuv
vaccin
one
mechan
induc
stronger
immun
respons
way
one
aspect
whole
organ
vaccin
make
success
fact
express
multipl
antigen
repetit
array
case
one
copi
b
cell
antigen
cell
viral
surfac
vaccin
recombin
protein
effect
occur
antigen
becom
dilut
patient
bodi
fluid
work
begin
would
lead
develop
anoth
mechan
gener
effect
vaccin
candid
would
close
mimic
whole
organ
vaccin
patient
infect
hepat
b
viru
hbv
produc
noninfecti
particl
blood
particl
actual
compos
protein
antigen
hbsag
present
envelop
hbv
hbsag
produc
larg
quantiti
infect
abl
selfassembl
nm
viruslik
particl
vlp
vlp
particl
resembl
size
shape
virus
contain
viral
genet
materi
mean
infecti
see
figur
quickli
identifi
vlp
time
immunogen
nonassembl
hbsag
particl
identifi
potenti
vaccin
candid
time
cultur
method
hbv
human
certain
nonhuman
primat
nhp
could
infect
propos
eventu
carri
best
mechan
develop
hbv
vaccin
harvest
plasma
asymptomat
volunt
chemic
treat
plasma
inactiv
like
infecti
particl
use
vaccin
candid
initi
studi
success
high
risk
popul
occur
late
earli
coincid
begin
acquir
human
immunodefici
aid
epidem
vaccin
approv
human
use
fear
use
human
blood
product
lack
volunt
cost
led
abandon
vaccin
eventu
withdraw
unit
state
recombin
hbsag
base
hbv
vaccin
becam
top
prioriti
dawn
recombin
vaccin
hbsag
produc
e
coli
immunogen
led
search
differ
express
host
hbsag
produc
natur
glycosyl
immunogen
form
cerevisia
vaccin
shown
immunogen
safe
vaccin
approv
still
remain
standard
hbv
vaccin
figur
tabl
recombin
hbsag
distinct
becom
first
approv
subunit
vaccin
also
first
approv
vlp
knowledg
use
develop
recombin
hbsag
vaccin
eventu
appli
diseas
hpv
lead
develop
clinic
approv
hpv
vaccin
also
becam
foundat
vaccin
advanc
malaria
vaccin
candid
rt
vlp
also
offer
advantag
repetit
antigen
display
consist
demonstr
antigen
display
repetit
increas
antibodi
titer
occur
increas
crosslink
b
cell
receptor
lead
b
cell
activ
vlp
made
viral
protein
process
apc
cell
viru
increas
effici
process
lead
activ
cell
also
increas
immun
respons
one
problem
vlp
everi
viru
vaccin
need
capsid
protein
selfassembl
immunogen
vlp
second
problem
everi
infecti
diseas
viru
diseas
success
fusion
construct
gener
rt
malaria
use
hbsag
carrier
gener
fusion
construct
alway
success
howev
problem
led
develop
new
technolog
would
incorpor
strength
vlp
minim
weak
excit
area
develop
vaccin
use
nanotechnolog
decemb
physicist
richard
feynman
gave
talk
entitl
plenti
room
bottom
predict
futur
scientist
would
abl
manipul
matter
atom
level
lead
develop
tini
manufactur
machin
k
eric
dexler
use
concept
feynman
advanc
genet
engin
propos
protein
could
design
carri
atom
level
fabric
dexler
eventu
publish
book
engin
creation
come
era
nanotechnolog
found
foresight
institut
direct
develop
nanotechnolog
karch
come
year
dexler
work
consid
true
begin
field
nanotechnolog
field
undergon
exponenti
growth
subsequ
three
decad
today
nanotechnolog
defin
unit
state
nation
nanotechnolog
initi
field
deal
nanoscal
object
nm
size
nanoparticl
defin
individu
nanoscal
object
abl
function
independ
unit
nanoscal
object
compos
wide
rang
materi
includ
organ
polym
inorgan
polym
biolog
macromolecul
nanoscal
assembl
divers
array
biomed
implic
includ
use
biolog
sensor
cell
target
system
drug
deliveri
system
subunit
vaccin
carrier
one
major
benefit
use
nanotechnolog
develop
vaccin
result
nanovaccin
design
effect
antigen
deliveri
system
attempt
made
mani
differ
type
nanomateri
develop
effect
vaccin
candid
nanotechnolog
uniform
field
rather
mixtur
mani
differ
nanoscal
materi
vari
chemic
composit
behavior
divers
field
led
develop
differ
approach
nanovaccin
group
advantag
disadvantag
make
unlik
one
approach
work
develop
necessari
vaccin
one
approach
use
differ
polym
copolym
polym
molecul
made
one
repeat
subunit
copolym
molecul
made
multipl
repeat
subunit
polymer
vaccin
made
broad
rang
compound
includ
llactidecoglycolid
plga
poli
lactic
acid
pla
poli
gglutam
acid
gpga
poli
ethylen
glycol
peg
polystyren
polym
either
function
encapsul
antigen
antigen
conjug
surfac
via
linker
antigen
adsorb
surfac
admix
antigen
chemistri
polym
interact
antigen
determin
effect
mechan
vaccin
deliveri
plga
nanoparticl
vaccin
prototyp
encapsul
vaccin
plga
wide
studi
year
varieti
biomed
applic
includ
drug
deliveri
diagnost
nanoparticl
consist
plga
core
made
desir
cargo
encapsul
polym
sinc
pgla
approv
food
drug
administr
fda
use
drug
deliveri
system
benefit
plga
nanoparticl
biomed
applic
slowli
degrad
expos
water
mean
protect
hydrophob
hydrophil
small
molecul
biolog
macromolecul
cargo
releas
extend
period
time
preclin
studi
demonstr
effect
carrier
mous
model
vaccin
compos
hbsag
tetanu
toxoid
helicobact
pylori
lysat
listeria
monocytogen
antigen
malaria
antigen
bacillu
anthraci
spore
vaccin
abl
gener
long
last
humor
cellular
immun
respons
also
given
oral
aerosol
subcutan
intraperiton
intermuscular
manner
natur
plga
strategi
taken
polym
base
nanoparticl
make
effect
vaccin
candid
synthet
vaccin
particl
svp
particl
use
carri
antigen
core
also
pamp
adjuv
encoat
phospholipid
decor
b
cell
antigen
lead
potenti
effici
vaccin
candid
function
repetit
antigen
display
deliveri
system
immunopotenti
polym
also
serv
inert
core
antigen
conjug
adsorpt
one
exampl
polystyren
bead
nanoparticl
solid
inert
core
also
known
nanobead
proof
principl
ovalbumin
vaccin
develop
vaccin
function
repetit
antigen
display
still
need
extern
adjuv
ad
gener
strong
immun
respons
comparison
vaccin
techniqu
better
stimul
immun
respons
polym
polystyren
thought
biocompat
howev
biodegrad
toxicolog
studi
cell
cultur
model
small
anim
indic
gener
free
radic
appear
caus
advers
effect
longterm
health
effect
known
howev
nanobead
inert
polym
core
function
repetit
antigen
display
still
need
adjuv
longterm
health
effect
unknown
make
ideal
candid
vaccin
develop
inorgan
molecul
also
use
deliveri
system
nanovaccin
one
best
studi
gold
nanoparticl
aunp
mani
materi
take
uniqu
chemic
physic
properti
nanoscal
level
gold
easili
modifi
nanoparticl
differ
size
shape
gold
also
take
uniqu
optic
properti
base
upon
nanoparticl
size
shape
attract
attent
use
cellular
imag
drug
deliveri
phototherm
therapi
studi
determin
aunp
appear
inert
biocompat
aunp
use
varieti
way
develop
vaccin
antigen
adsorb
conjug
surfac
size
shape
aunp
link
function
vaccin
candid
differ
geometr
shape
lead
differenti
apc
phagocytosi
antigen
present
find
also
indic
aunp
function
effect
deliveri
system
vaccin
success
preclin
vaccin
candid
develop
diseas
influenza
west
nile
viru
plagu
also
interest
initi
studi
develop
prophylact
therapeut
cancer
vaccin
base
aunp
despit
fact
aunp
easili
modifi
immunogen
shape
size
publish
studi
extern
adjuv
need
ad
gener
protect
effect
vaccin
candid
carbon
nanotub
cnt
anoth
class
inorgan
nanoparticl
interest
vaccin
develop
sheet
graphen
fold
tube
shape
occur
singl
layer
singlewal
carbon
nanotub
swnt
multipl
layer
multiwal
carbon
nanotub
mwnt
cnt
mani
advantag
make
ideal
candid
vaccin
develop
larg
surfac
area
make
excel
potenti
repetit
antigen
display
adsorpt
conjug
antigen
surfac
fairli
easi
studi
indic
highli
immunogen
could
potenti
indic
besid
function
antigen
deliveri
karch
system
also
could
function
immunopotenti
one
major
problem
applic
cnt
vaccinolog
toxicolog
establish
studi
highli
conflict
inorgan
nanoscal
assembl
base
silica
aluminum
calcium
phosphat
use
attempt
develop
effect
vaccin
candid
howev
mani
problem
occur
class
primari
issu
longterm
health
effect
known
initi
studi
focus
vitro
model
small
anim
model
everi
class
inorgan
nanoparticl
studi
indic
form
toxicolog
benefit
class
lack
understand
longterm
health
effect
make
develop
clinic
product
difficult
current
time
first
propos
dexler
use
biolog
molecul
mani
advantag
develop
nanotechnolog
particularli
nanovaccin
first
approv
subunit
vaccin
hbv
vaccin
technic
nanoparticl
compos
complet
protein
vlp
made
hbsag
selfassembl
nm
particl
fall
well
nm
design
nanoscal
assembl
biolog
base
technolog
also
develop
repetit
display
antigen
potenti
lower
level
toxic
comparison
inorgan
synthet
polym
nanoparticl
capit
biolog
macromolecul
scientist
abl
develop
vaccin
candid
close
resembl
microorgan
mean
function
effici
insid
host
one
exampl
biolog
deriv
nanoparticl
liposom
phospholipid
bilay
surround
aqueou
chamber
note
phospholipid
could
assembl
structur
first
studi
came
indic
liposom
could
function
adjuv
increas
immun
respons
diphtheria
toxoid
vaccin
contain
aqueou
chamber
subsequ
year
studi
establish
liposom
safe
effect
antigen
deliveri
system
well
adjuv
liposom
extrem
plastic
mean
size
shape
charg
phospholipid
composit
support
molecular
composit
alter
elicit
desir
effect
function
repetit
antigen
display
antigen
either
incorpor
phospholipid
bilay
adsorb
onto
membran
liposom
also
carri
cell
epitop
cargo
aqueou
chamber
studi
indic
liposom
function
two
main
reason
fact
compos
phospholipid
increas
abil
apc
cell
phagocytos
particl
lead
increas
antigen
process
present
studi
indic
cation
liposom
effect
adjuv
remain
longer
associ
cell
membran
electrostat
interact
longer
liposom
associ
membran
higher
probabl
apc
phagocytos
present
antigen
liposom
also
carri
extern
adjuv
chamber
karch
adjuv
like
pamp
incorpor
membran
lead
stronger
immun
respons
virosom
could
consid
cross
vlp
liposom
tradit
virosom
compos
phospholipid
contain
envelop
influenza
viru
along
viral
envelop
protein
hemagglutinin
neuraminidas
design
particl
function
immunogen
influenza
virus
contain
genom
unabl
replic
demonstr
increas
fusion
apc
subsequ
elev
antigen
present
phospholipid
envelop
protein
origin
isol
influenza
viral
cultur
grown
embryon
egg
synthet
produc
assembl
liposom
antigen
ad
membran
adsorb
onto
membran
carri
cargo
virosom
two
differ
virosom
use
success
sinc
human
first
inflex
influenza
vaccin
second
epax
formalin
inactiv
hepati
adsorb
influenza
virosom
vaccin
shown
effect
good
safeti
profil
also
demonstr
virosom
function
antigen
deliveri
system
well
adjuv
current
vaccin
malaria
hepat
c
variou
cancer
hiv
candida
albican
variou
stage
clinic
develop
use
influenza
virosom
core
nanoparticl
compos
protein
selfassembl
repetit
antigen
display
area
intens
interest
develop
nanovaccin
one
class
nanoscal
assembl
deriv
protein
ferritin
figur
ferritin
iron
metabol
protein
present
bacteria
anim
plant
normal
condit
monom
ferritin
selfassembl
spheric
particl
octahedr
symmetri
contain
open
central
caviti
structur
known
ferritin
cage
ferritin
cage
overal
diamet
nm
core
diamet
nm
starvat
bacteri
ferritin
assembl
particl
tetramer
symmetri
compos
ferritin
monom
ferritin
cage
use
wide
varieti
biomed
applic
includ
medic
imag
drug
deliveri
studi
determin
ferritin
cage
function
vaccin
deliveri
system
hemagglutinin
subtyp
influenza
fuse
ferritin
h
pylori
lead
gener
influenza
vaccin
candid
result
particl
express
eight
trimer
hemagglutinin
molecul
nativ
conform
vertic
particl
vaccin
ferret
anim
develop
antibodi
head
domain
stalk
domain
hemagglutinin
challeng
anim
protect
head
domain
hemagglutinin
influenza
immunodomin
subject
antigen
drift
necessit
season
chang
vaccin
formul
desir
gener
vaccin
candid
focus
conserv
stem
domain
recombin
ferritin
molecul
gener
lack
head
domain
construct
abl
rais
stalk
specif
antibodi
complet
protect
mice
challeng
partial
protect
ferret
karch
ferritin
cage
excit
potenti
repetit
display
antigen
candid
weak
ferritin
cage
rigid
assembl
antigen
need
present
certain
conform
immunogen
ferritin
cage
may
abl
present
immunogen
form
ferritin
cage
seem
like
excel
candid
develop
vaccin
abl
use
everi
antigen
anoth
natur
occur
nanoscal
assembl
attract
attent
vault
protein
figur
protein
natur
occur
eukaryot
may
play
role
nuclear
transport
signal
transduct
innat
immun
respons
exact
function
establish
vault
nm
organellelik
structur
compos
three
protein
major
vault
protein
mvp
make
complex
telomeras
associ
poli
adpribos
polymeras
parp
noncod
rna
vault
design
express
heterolog
protein
insid
central
caviti
easili
done
ad
specif
sequenc
protein
determin
associ
parp
protein
mvp
vault
immunogen
lead
develop
autoimmun
respons
make
good
vaccin
deliveri
system
use
model
protein
ovalbumin
vault
success
induc
c
h
respons
vaccin
anim
less
success
induc
humor
immun
respons
vault
develop
vaccin
candid
chlamydia
muridarium
infect
inocul
induc
h
c
respons
lead
protect
challeng
despit
success
vault
biggest
weak
antigen
contain
within
vault
caviti
prevent
stimul
b
cell
lead
strong
humor
respons
current
vault
could
function
strong
vaccin
candid
intracellular
pathogen
diseas
cancer
develop
need
use
wide
rang
pathogen
natur
occur
nanoscal
assembl
good
vaccin
candid
certain
infecti
diseas
may
applic
wide
rang
infecti
organ
anoth
approach
develop
nanovaccin
use
ration
design
protein
combin
knowledg
structur
biolog
biophys
protein
engin
infecti
diseas
biolog
molecular
biolog
new
protein
develop
function
ideal
vaccin
candid
approach
consid
bottomup
approach
take
small
part
gener
complex
assembl
vlp
approach
topdown
approach
take
complex
protein
assembl
strip
basic
compon
term
vaccin
would
smallest
part
induc
protect
immun
mani
benefit
challeng
associ
vaccin
develop
bottomup
ration
design
protein
major
benefit
design
protein
function
repetit
antigen
display
wide
rang
antigen
limit
like
ferritin
cage
vault
conform
antigen
present
also
optim
induc
strong
cellular
humor
immun
respons
addit
new
antigen
domain
function
protein
need
abl
selfassembl
use
noncoval
interact
nanoscal
assembl
selfassembl
need
occur
without
ad
enzym
specif
reproduc
manner
major
drawback
approach
protein
sequenc
matter
well
design
alway
perfectli
correl
structur
function
problem
lead
need
design
empir
test
optim
achiev
desir
structur
ultim
desir
protect
effect
vaccin
anim
techniqu
appli
develop
ration
design
protein
nanoparticl
layerbylay
lbl
fabric
polypeptid
film
solid
caco
core
method
polypeptid
layer
altern
opposit
charg
deposit
caco
nanoparticl
core
electrostat
interact
opposit
charg
polypeptid
layer
keep
particl
togeth
contain
within
differ
layer
differ
b
cell
antigen
ad
allow
develop
vaccin
candid
differ
diseas
state
malaria
respiratori
syncyti
viru
rsv
vaccin
candid
design
use
approach
immunogen
capabl
rais
neutral
antibodi
either
malaria
rsv
respect
malaria
candid
abl
gener
cellular
respons
well
one
approach
develop
ration
design
protein
nanoparticl
nanofib
nanoscal
assembl
deriv
secondari
structur
initi
design
nanofib
core
consist
amino
acid
could
selfassembl
unbranch
antiparallel
initi
design
purpos
regen
medicin
nanofib
determin
nonimmunogen
well
toler
anim
amino
acid
fragment
ovalbumin
establish
b
epitop
ad
n
terminu
construct
nanofib
selfassembl
function
repetit
antigen
display
antibodi
titer
vaccin
anim
greater
anim
vaccin
ovalbumin
fragment
fca
anoth
studi
also
indic
anim
vaccin
nanofib
contain
c
epitop
ovalbumin
develop
strong
c
respons
initi
prototyp
studi
determin
nanofib
could
function
success
vaccin
candid
nanofib
success
use
infecti
diseas
model
well
vaccin
candid
malaria
abl
induc
high
titer
antibodi
function
prevent
infect
vitro
assay
attempt
made
increas
h
respons
nanofib
ad
panallel
dr
epitop
padr
univers
h
epitop
heterogen
mixtur
epitop
use
develop
staphylococcu
aureu
vaccin
candid
addit
padr
result
antibodi
titer
increas
padr
concentr
relat
manner
success
nanofib
technolog
instanc
nanofib
elicit
strong
immun
respons
nanofib
success
applic
ration
design
protein
nanoparticl
mani
problem
exist
use
core
sequenc
amino
acid
long
extrem
short
prevent
addit
larg
antigen
allow
addit
short
region
antigen
sever
limit
immunogen
short
peptid
need
chemic
synthes
epitop
tag
express
protein
express
system
fact
limit
abil
scale
cost
effect
manner
karch
one
appeal
protein
structur
motif
ration
design
nanovaccin
coiledcoil
oligomer
domain
motif
consist
two
wrap
around
coiledcoil
one
common
best
understood
stabl
oligomer
domain
one
applic
coiledcoil
oligomer
domain
vaccin
design
synthet
viru
like
particl
svlp
particl
base
chemic
synthes
monom
consist
lipid
attach
coiledcoil
trimer
domain
chemic
attach
antigen
base
basic
biophys
properti
monom
selfassembl
nm
particl
contain
lipid
core
surfac
decor
antigen
svlp
function
repetit
antigen
display
capabl
induc
humor
respons
vaccin
anim
perhap
one
promis
nanoscal
assembl
vaccin
develop
selfassembl
protein
nanoparticl
sapn
figur
sapn
ration
design
repetit
antigen
display
function
divers
array
antigen
diseas
antigen
ad
either
c
n
terminu
sapn
monom
prototyp
sapn
monom
selfassembl
particl
regular
symmetri
assembl
sapn
decor
surfac
copi
antigen
make
excel
repetit
antigen
display
figur
sapn
function
repetit
antigen
display
individu
particl
resembl
small
virus
shape
well
size
nm
togeth
factor
make
excel
immunostimulatori
particl
prime
vaccin
candid
one
major
benefit
sapn
design
wide
varieti
coiledcoil
oligomer
domain
natur
coiledcoil
exist
consist
member
coiledcoil
domain
synthes
laboratori
bcell
epitop
conform
mean
epitop
base
structur
antigen
linear
sequenc
toolbox
wellestablish
wellunderstood
coiledcoil
oligomer
domain
allow
present
antigen
particular
oligomer
antigen
nativ
conform
best
immunogen
present
chosen
develop
effect
vaccin
candid
choos
differ
oligomer
domain
ultim
chang
geometri
sapn
particl
howev
still
selfassembl
function
effect
repetit
antigen
display
anoth
entic
featur
sapn
abil
add
univers
h
epitop
core
sapn
use
effect
vaccin
candid
varieti
diseas
success
candid
develop
viral
diseas
avian
influenza
sar
hiv
viral
diseas
sapn
technolog
appli
high
antibodi
titer
observ
case
antibodi
demonstr
function
vitro
assay
one
challeng
class
infecti
agent
develop
vaccin
parasit
diseas
parasit
complex
organ
multipl
life
stage
immun
avoid
mechan
gener
infect
multipl
host
sapn
effect
develop
parasit
vaccin
candid
sapn
candid
induc
strong
humor
cellular
immun
respons
malaria
murin
model
lead
protect
challeng
sapn
also
shown
immunogen
abl
induc
protect
challeng
murin
model
toxoplasma
gondii
success
demonstr
strength
sapn
vaccin
technolog
sinc
jenner
develop
first
vaccin
candid
great
advanc
made
field
infecti
diseas
vaccinolog
despit
advanc
made
still
much
work
done
field
move
tradit
method
vaccin
develop
organ
cultur
attenu
kill
could
becom
effect
vaccin
candid
today
modern
biolog
techniqu
extrem
target
safer
vaccin
develop
much
quickli
ever
major
problem
candid
tend
less
immunogen
ultim
less
protect
whole
organ
vaccin
resolv
issu
current
main
focu
vaccin
develop
current
need
rapid
effect
develop
infecti
diseas
vaccin
besid
big
three
diseas
need
vaccin
hiv
tuberculosi
malaria
outbreak
new
emerg
diseas
ebola
zika
viru
threaten
global
public
health
new
technolog
may
provid
mechan
quick
develop
rapid
implement
vaccin
develop
vaccin
technolog
includ
immunostimulatori
molecul
well
epitop
better
vaccin
candid
gener
vaccinolog
disciplin
tradit
focus
develop
vaccin
prevent
infecti
diseas
uniqu
relationship
allow
vaccinolog
develop
hand
hand
immunolog
infecti
diseas
biolog
knowledg
disciplin
increas
allow
develop
new
vaccin
technolog
appli
diseas
state
cancer
develop
vaccin
technolog
continu
refin
improv
applic
becom
avail
diseas
state
cancer
addict
obes
potenti
near
futur
scientist
abl
appli
new
technolog
develop
prophylact
treatment
broad
rang
diseas
lead
decreas
global
morbid
mortal
everyth
infecti
diseas
cancer
vaccinolog
first
year
develop
scratch
surfac
possibl
timelin
show
differ
class
vaccin
becam
clinic
avail
overlap
avail
vaccin
like
hepat
b
technic
fall
multipl
class
subunit
well
nanovaccin
lighterdash
color
indic
class
like
remain
import
forese
futur
karch
show
rna
bacteriophag
q
beta
form
icosahedr
particl
pdbrcsb
code
view
twofold
axi
icosahedron
c
ferritin
shown
octahedr
structur
ferritin
marin
pennat
diatom
pseudonitzschia
multiseri
pmftn
pdbrcsb
code
view
fourfold
axi
octahedron
sapn
exampl
show
sapn
compos
pentamer
blue
trimer
cyan
coiledcoil
domain
display
trimer
coiledcoil
epitop
hrc
red
sar
coronaviru
view
threefold
axi
icosahedron
karch
biochem
pharmacol
author
manuscript
avail
pmc
novemb
